MewTaxel

CORPORATE OVERVIEW

Our mission is to develop a most effective and safe formulation for

Paclitaxel (MewTaxol) for cancer treatment.

The Company

New Co (MewTaxol Inc.) has developed a new Hybrid Paclitaxel (MewTaxol) to treat cancer with its double edge mode of action. The Company has developed the hybrid drug MewTaxel which is ready for clinical trials. Our 1^st exit plan is $100-500M within 5 years.

Since the discovery of this hybrid platform NewCo has been investing its resources to develop a better or I would say the best formulation of Hybrid Paclitaxel (MewTaxol). NewCo always look for a better solution for cancer treatment. At this point, Mewtaxol needs funds for clinical trials and FDA filing.

Office is located in Baton Rouge, LA70791. The company has its collaborations with Meda Biotech LLc., USA and Nano Biotech

(P) Ltd., India.

The

Problem

History

Opportunity

Currently, about 30% of drugs that appear on the World Health Organization (WHO) Essential Drug List were reported to be poorly water-soluble, based on the Biopharmaceutics Classification System (BCS).

Over 40% of newly developed pharmaceutically active substances have solubility issues.

The poor dissolution and/or permeability of these drugs often result in low and highly variable bioavailability.

The major obstacle of successfully commercializing these compounds is the difficulty of enhancing their dissolution rate and extent of dissolution

Paclitaxel molecule discovered in 1960s through NCI program (Wani and Wall)

1992 : FDA approval of Taxol (paclitaxel)

The best new cancer drug in 30 years

Extracted from bark of the Pacific Yew Tree, extremely insoluble

Formulated with surfactant Cremophor - polyoxyethylated castor oil + ethanol for IV

administration

Causes Anaphylaxis and respiratory arrest, and severe hypersensitivity

Poor pharmacokinetic profile is still a problem

High levels of neutropenia and long lasting neuropathy

We believe there is still a lot of room to make this novel drug better than newest formulation called Abraxane and other. So we come up with MewTaxol Exclusive licensing agreements are signed to use the technology for MewTaxel. and each receives a royalty on the net selling price.

Market

Potential

Competition

MewTaxel is the newest discovery for Hybrid Paclitaxel. It has a potential to beat existing formulation , thereby entering the $4.9 billion cancer treatment market

MewTaxel is a patented Hybrid Paclitaxel drug which exploits the intact properties of two drugs to achieve a safe ,solvent free, surfactant free, protein free water soluble formulation. Mewtaxol is more potent and safe formulation. The drug is easy to manufacture and easy to administer. Open field to enter.

R $5B MARKET FREE FROM PATENT

R CAPTURE THE MARKET WITH NEW PATENT PROTECTION

R EITHER BY IMPROVEMENT

R EITHER BY CHANGING THE MOLECULE

R EITHER BY CONJUGATION OR HYBRIDIZATION

R DECREASE TOXICITY

R INCREASE EFFICACY

R OUR TECHNOLOGY IS SIMPLE (WITHOUT ANY POLYMER CONJUGATION) HYBRID. MANUFACTURING COST IS LOW

Major competition is a newly approved protein conjugated Paclitaxel named Abraxane, our hybrid MewTaxol should be a better choice for future. A double edge approach to treat cancer.

Customer Demand/

Expansion

• Paclitaxel is already approved for Breast cancer, Lung cancer, ovarian cancer, Kaposi sarcoma and Pancreas cancer.
• Many ongoing trials are there in combination of other drugs will make this even a bigger market expansion.
• A double edge approach should be a winner.

Team

Mewa Singh, 609-902-7128, [email protected]

Achievement

And

Financial Overview

Proof of concept, R&D and pilot scale production procedures are in place, no more dead investment is needed.

A Total of $10-25M is needed to take this drug for FDA submissions and clinical phase.